Is AnaptysBio Inc halal to invest in?

According to Musaffa's Shariah screening methodology, AnaptysBio Inc (ANAB) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is AnaptysBio Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes AnaptysBio Inc using these criteria to determine its compliance status.

Can Muslims buy shares of AnaptysBio Inc?

Muslim investors may consider investing in AnaptysBio Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is AnaptysBio Inc classified as NOT HALAL?

Musaffa determines the Shariah status of AnaptysBio Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for AnaptysBio Inc updated?

The Shariah compliance status of AnaptysBio Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like AnaptysBio Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of AnaptysBio Inc?

You can check the latest Shariah compliance status of AnaptysBio Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ANAB Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 04, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for AnaptysBio Inc (ANAB)

Based on 19 analysts giving stock ratings to AnaptysBio Inc in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

AnaptysBio Inc. Stock Analysis ANAB

United States Health Care Mid Cap Report: 2025 Annual

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2017-01-26. The firm manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The firm's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The firm's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).

Key Statistics of AnaptysBio Inc (ANAB)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$60.93$64.36

Today's Open

$62.19

Volume

448.36K

P/E Ratio (TTM)

52 Week Range

$17.11$73.30

Market Cap

2.02B

Avg. Volume

725.03K

Dividend Yield

Financial Metrics & Statements of AnaptysBio Inc (ANAB)

FAQ's for AnaptysBio Inc (ANAB)

According to Musaffa’s Shariah screening methodology, AnaptysBio Inc (ANAB) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.